Elanix Biotechnologies AG
Elanix Biotechnologies Launches Adherence App for GYNrepair(R) Women’s Intimate Health Cream
DGAP-News: Elanix Biotechnologies AG / Key word(s): Miscellaneous
PRESS RELEASE Elanix Biotechnologies Launches Adherence App for GYNrepair(R) Women’s Intimate Health Cream App Reminds Women to Reapply, Helps Monitor Discomfort Relief Digital Platform Supports GYNrepair EU Commercialization The app* allows women to easily monitor their external intimate zone discomfort, by logging and tracking daily feeling of, among others, discomfort, twinges and dryness, which also assists in discussions with their doctor. Alerts can be set so that each day users are reminded to apply the cream and to identify on a 1-10 scale, the level of their intimate discomfort. These alerts can help women to benefit continuously from the soothing properties of GYNrepair(R) cream and build application times into their daily schedules. As each application has a recommended volume, the app automatically estimates when a refill is needed and offers one click to the website where it can be re-ordered. The app is available in English, French and German and can be downloaded from the App Store and Google Play Store. “Smartphone apps are revolutionizing delivery of healthcare, particularly in the field of adherence. Our user-friendly app will help women schedule recommended application of GYNrepair(R) cream into their busy lives. Elanix will continue to explore how additional features on the app can provide benefits to our customers,” stated Tomas Svoboda, CEO of Elanix Biotechnologies. “We have developed the app to support commercialization expansion for GYNrepair(R) cream and provide an easy to use, direct interface to our customers. This interaction with our customers, we believe, will help drive commercial success for the product.” *Disclaimer – The app does not store personal data and is not intended for diagnostic purposes. About Women’s Intimate Health REPAIR-A is dedicated to the development and marketing of progenitor cell based CFPC(R) Elanix Biotechnologies AG (FRA: ELN) develops and commercializes tissue regeneration products for acute wound care, dermatological and gynecological applications, and provides services in cell technologies. The company was founded in 2012 as a spin-out from the University Hospital of Lausanne (CHUV), Switzerland, to commercialize a patented human progenitor cell technology. Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing. Elanix owns GMP certified Master and Working human cell banks with vast quantities of cells.
Disclaimer / Forward-looking statements:
27.06.2017 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |
Language: | English |
Company: | Elanix Biotechnologies AG |
Domstr. 22 | |
14482 Potsdam | |
Germany | |
ISIN: | DE000A0WMJQ4 |
WKN: | A0WMJQ |
Listed: | Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf |
End of News | DGAP News Service |